Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Morphic Holding Inc
(NQ:
MORF
)
56.99
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Morphic Holding Inc
< Previous
1
2
3
Next >
Morphic Holding, Inc. Reminder: Robbins LLP is Investigating MORF on Behalf of Investors
November 22, 2023
From
Robbins LLP
Via
Business Wire
Morphic to Present at November Investor Conferences
November 10, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
November 03, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 7/17
July 17, 2023
Via
Investor Brand Network
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 6/5
June 05, 2023
Via
Investor Brand Network
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 5/10
May 10, 2023
Via
Investor Brand Network
NASDAQ: MORF Investor Notice: Investigation over Possible Securities Laws Violations by Morphic Holding, Inc.
November 01, 2023
San Diego, CA -- (SBWIRE) -- 11/01/2023 -- Morphic Holding, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Morphic Holding Investigation: Johnson Fistel Encourages Shareholders with Losses to Contact the Firm Regarding Investigation
October 21, 2023
From
Johnson Fistel, LLP
Via
Business Wire
Morphic Holding SHAREHOLDER ALERT: Johnson Fistel Encourages Morphic Holding Shareholders with Losses to Contact the Firm Regarding Investigation
October 14, 2023
From
Johnson Fistel, LLP
Via
Business Wire
Morphic Holding Inc. (NASDAQ: MORF) Highlighted for Surprising Price Action
April 17, 2023
Via
Investor Brand Network
Morphic Holding Inc. (NASDAQ: MORF) Leading the Way in Monday Trading Based on Percentage Gain
April 17, 2023
Via
Investor Brand Network
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
October 09, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
MORF INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
September 29, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence
September 26, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
September 22, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
August 29, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 09, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
August 03, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present at the Jefferies Global Healthcare Conference
June 06, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
May 12, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
May 11, 2023
-Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition-
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 05, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
May 03, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Therapeutic Announces Proposed Public Offering
May 02, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
April 25, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
April 25, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
April 24, 2023
Call to discuss topline data from EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present at TD Cowen 43rd Annual Health Care Conference
March 03, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022
February 23, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present at SVB Leerink Global Healthcare Conference
February 14, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.